瑞聲(02018.HK)料第四季光學模組及塑膠鏡頭出貨量恢復正常
瑞聲科技(02018.HK)投資者關係總監黃美娟表示,受疫情及供應鏈短缺影響,第三季有部分客戶推遲及取消部分機型的訂單,導致需求減弱,拖累業績表現,相信隨着上遊晶片短缺情況有所緩解及訂單恢復,光學業務中塑膠鏡頭及光學模組出貨量將可恢復至正常水平,公司將透過改善產品組合以提升盈利能力。
公司目標將非智能手機業務佔精密結構件收入比例提升至15%以上,她預期,早前收購東陽精密可有助於現有業務發展。
談及未來回購計劃及股價表現,董事總經理莫祖權表示,提振股價應由市場主導,認爲在近期經濟環境下,市場會對瑞聲等被低估的公司有「更好反應」。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.